The next generation biopharmaceuticals
Scientific Advisory Board
Prof. Hans Wigzell, M.D., Ph.D.
Professor Emeritus of Microbiology and Tumor Biology, Karolinska Institutet
Prof. Mathias Uhlén, Ph.D.
Professor of Microbiology, Royal Institute of Technology
Affibodys latest Press releases
Affibody, ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 European Alliance of Associations for Rheumatology Congress
Affibody in short
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Upcoming reports Financial calendar
- Interim Report January to March 2020 (May 15, 2020)
- Interim Report January to June 2020 (August 21, 2020)
- Interim Report January to September 2020 (November 13, 2020)
- Year End Report 2020 (February 2021)